Top Healthcare Stocks
Healthcare stocks were posting slim losses Thursday with the
NYSE Healthcare Sector Index declining about 0.1% and shares of
healthcare companies in the S&P 500 down less than 0.1% as a
In company news, Protalix BioTherapeutics Inc. (
) rallied after the U.S. Food and Drug Administration (FDA)
approved its Elelyso injection to also treat pediatric patients
with a confirmed diagnosis of Type 1 Gaucher disease.
The agency previously approved the replacement therapy developed
by RLX in collaboration with Pfiser (
) for use in older patients with the genetic disease causing fatty
substances to accumulate in cells and certain organ.
PLX shares were ahead about 9.5% in late trade at $2.64 apiece,
earlier climbing to a session high of $3.00 a share. The stock has
traded within a 52-week range of $2.35 to $5.60 a share, declining
over 53% over the past 12 months.
PFE recently was down 0.2% at $29.43 a share.
In other sector news,
(+) RPRX, Said its Androxal testosterone-replacement oral drug
outperformed an FDA-approved gel and a placebo in the first of two
identical studies, with patients taking Androxal achieved higher
sperm concentrations than those in other study arms.
(-) IG, Receives Outperform rating in new coverage today at
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.